News
Press Releases
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
-
Sep 27, 2023
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced the outcome of the U.S. Food and Drug...
-
Sep 27, 2023
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced that Nasdaq has halted trading of the...
-
Aug 14, 2023
FDA advisory committee (ADCOM) meeting to discuss NurOwn® for Amyotrophic Lateral Sclerosis (ALS) scheduled for September 27, 2023 BrainStorm's Biologics License Application (BLA) for NurOwn has...
-
Aug 7, 2023
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, announced today that it will hold a conference call to update...
-
Jul 17, 2023
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI) (the "Company"), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced that it has entered into a...
-
Jul 12, 2023
Dr. Dagher has extensive biopharma industry expertise in the development and approval of treatments for challenging neurological and rare diseases NEW YORK, July 12, 2023 /PRNewswire/ --...
-
Jul 7, 2023
New data presented this week at Gordon Research Conference Analysis reinforces NfL levels as predictive of ALS clinical outcomes NEW YORK, July 7, 2023 /PRNewswire/ -- BrainStorm Cell Therapeutics...
-
Jun 20, 2023
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced the appointment of Nir Naor, CPA, CFA, MBA...
-
Jun 16, 2023
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced that Dr. Stacy Lindborg, Co-Chief Executive...
-
Jun 6, 2023
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced that the U.S. Food and Drug Administration...
Tools
Investors
- Overview
- News
- Events & Presentations
- Stock Information
- Financial Reports & Filings
- Corporate Governance